Haptoglobin proved a prognostic biomarker in peripheral blood of patients with personalized peptide vaccinations for advanced castration-resistant prostate cancer

Xiaoliang Pang, Kosuke Tashiro, Rieko Eguchi, Nobukazu Komatsu, Tetsuro Sasada, Kyogo Itoh, Satoru Kuhara

研究成果: ジャーナルへの寄稿記事

7 引用 (Scopus)

抄録

Haptoglobin (Hp) is a well-known acute-phase protein that possibly has influence on tumors through the immune response. This study was conducted to evaluate the correlation between Hp expression and the effect of treatment by cancer peptide vaccines in advanced castration-resistant prostate cancer (CRPC) patients. Hp expression was measured by RT-PCR using peripheral blood mononuclear cells (PBMCs) collected from advanced CRPC patients, who were divided into two groups: long-term survivors and short-term survivors. Before cancer peptide vaccination (pre-vaccination), Hp expression was almost same in the two groups, but after cancer peptide vaccination (post-vaccination), Hp expression was higher in short-term survivors, suggesting that Hp expression in the PBMCs increased in shortterm survivors after treatment by cancer peptide vaccines. Our results suggest that Hp expression level in the PBMCs can serve as a prognostic biomarker in treatment by cancer peptide vaccine in advanced CRPC patients.

元の言語英語
ページ(範囲)766-770
ページ数5
ジャーナルBioscience, Biotechnology and Biochemistry
77
発行部数4
DOI
出版物ステータス出版済み - 6 14 2013

Fingerprint

Haptoglobins
Castration
Biomarkers
Prostatic Neoplasms
Vaccination
Blood
Peptides
Cancer Vaccines
Subunit Vaccines
Survivors
Blood Cells
Neoplasms
Acute-Phase Proteins
Tumors
Therapeutics
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Applied Microbiology and Biotechnology
  • Analytical Chemistry
  • Organic Chemistry

これを引用

Haptoglobin proved a prognostic biomarker in peripheral blood of patients with personalized peptide vaccinations for advanced castration-resistant prostate cancer. / Pang, Xiaoliang; Tashiro, Kosuke; Eguchi, Rieko; Komatsu, Nobukazu; Sasada, Tetsuro; Itoh, Kyogo; Kuhara, Satoru.

:: Bioscience, Biotechnology and Biochemistry, 巻 77, 番号 4, 14.06.2013, p. 766-770.

研究成果: ジャーナルへの寄稿記事

Pang, Xiaoliang ; Tashiro, Kosuke ; Eguchi, Rieko ; Komatsu, Nobukazu ; Sasada, Tetsuro ; Itoh, Kyogo ; Kuhara, Satoru. / Haptoglobin proved a prognostic biomarker in peripheral blood of patients with personalized peptide vaccinations for advanced castration-resistant prostate cancer. :: Bioscience, Biotechnology and Biochemistry. 2013 ; 巻 77, 番号 4. pp. 766-770.
@article{3ad3cb73743b406d874fe7cfc0b9d0b2,
title = "Haptoglobin proved a prognostic biomarker in peripheral blood of patients with personalized peptide vaccinations for advanced castration-resistant prostate cancer",
abstract = "Haptoglobin (Hp) is a well-known acute-phase protein that possibly has influence on tumors through the immune response. This study was conducted to evaluate the correlation between Hp expression and the effect of treatment by cancer peptide vaccines in advanced castration-resistant prostate cancer (CRPC) patients. Hp expression was measured by RT-PCR using peripheral blood mononuclear cells (PBMCs) collected from advanced CRPC patients, who were divided into two groups: long-term survivors and short-term survivors. Before cancer peptide vaccination (pre-vaccination), Hp expression was almost same in the two groups, but after cancer peptide vaccination (post-vaccination), Hp expression was higher in short-term survivors, suggesting that Hp expression in the PBMCs increased in shortterm survivors after treatment by cancer peptide vaccines. Our results suggest that Hp expression level in the PBMCs can serve as a prognostic biomarker in treatment by cancer peptide vaccine in advanced CRPC patients.",
author = "Xiaoliang Pang and Kosuke Tashiro and Rieko Eguchi and Nobukazu Komatsu and Tetsuro Sasada and Kyogo Itoh and Satoru Kuhara",
year = "2013",
month = "6",
day = "14",
doi = "10.1271/bbb.120893",
language = "English",
volume = "77",
pages = "766--770",
journal = "Bioscience, Biotechnology and Biochemistry",
issn = "0916-8451",
publisher = "Japan Society for Bioscience Biotechnology and Agrochemistry",
number = "4",

}

TY - JOUR

T1 - Haptoglobin proved a prognostic biomarker in peripheral blood of patients with personalized peptide vaccinations for advanced castration-resistant prostate cancer

AU - Pang, Xiaoliang

AU - Tashiro, Kosuke

AU - Eguchi, Rieko

AU - Komatsu, Nobukazu

AU - Sasada, Tetsuro

AU - Itoh, Kyogo

AU - Kuhara, Satoru

PY - 2013/6/14

Y1 - 2013/6/14

N2 - Haptoglobin (Hp) is a well-known acute-phase protein that possibly has influence on tumors through the immune response. This study was conducted to evaluate the correlation between Hp expression and the effect of treatment by cancer peptide vaccines in advanced castration-resistant prostate cancer (CRPC) patients. Hp expression was measured by RT-PCR using peripheral blood mononuclear cells (PBMCs) collected from advanced CRPC patients, who were divided into two groups: long-term survivors and short-term survivors. Before cancer peptide vaccination (pre-vaccination), Hp expression was almost same in the two groups, but after cancer peptide vaccination (post-vaccination), Hp expression was higher in short-term survivors, suggesting that Hp expression in the PBMCs increased in shortterm survivors after treatment by cancer peptide vaccines. Our results suggest that Hp expression level in the PBMCs can serve as a prognostic biomarker in treatment by cancer peptide vaccine in advanced CRPC patients.

AB - Haptoglobin (Hp) is a well-known acute-phase protein that possibly has influence on tumors through the immune response. This study was conducted to evaluate the correlation between Hp expression and the effect of treatment by cancer peptide vaccines in advanced castration-resistant prostate cancer (CRPC) patients. Hp expression was measured by RT-PCR using peripheral blood mononuclear cells (PBMCs) collected from advanced CRPC patients, who were divided into two groups: long-term survivors and short-term survivors. Before cancer peptide vaccination (pre-vaccination), Hp expression was almost same in the two groups, but after cancer peptide vaccination (post-vaccination), Hp expression was higher in short-term survivors, suggesting that Hp expression in the PBMCs increased in shortterm survivors after treatment by cancer peptide vaccines. Our results suggest that Hp expression level in the PBMCs can serve as a prognostic biomarker in treatment by cancer peptide vaccine in advanced CRPC patients.

UR - http://www.scopus.com/inward/record.url?scp=84878812823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878812823&partnerID=8YFLogxK

U2 - 10.1271/bbb.120893

DO - 10.1271/bbb.120893

M3 - Article

C2 - 23563546

AN - SCOPUS:84878812823

VL - 77

SP - 766

EP - 770

JO - Bioscience, Biotechnology and Biochemistry

JF - Bioscience, Biotechnology and Biochemistry

SN - 0916-8451

IS - 4

ER -